HC Wainwright Lowers LifeMD (NASDAQ:LFMD) Price Target to $13.00

Key Points

• HC Wainwright has lowered the price target for LifeMD (NASDAQ:LFMD) from $14.00 to $13.00, while maintaining a "buy" rating, indicating a potential upside of 99.08% from current prices.
• LifeMD's shares are down 44.8% and currently trade at $6.53, with a market capitalization of $296.79 million.
• The company has received mixed ratings from analysts, with five analysts$12.86.

LifeMD (NASDAQ:LFMD - Free Report) had its price target trimmed by HC Wainwright from $14.00 to $13.00 in a research note released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for LifeMD's Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.20 EPS and FY2026 earnings at $0.47 EPS.

A number of other equities research analysts have also recently issued reports on LFMD. Wall Street Zen cut shares of LifeMD from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. BTIG Research raised their price objective on shares of LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, June 18th. Lake Street Capital dropped their price objective on shares of LifeMD from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Finally, KeyCorp lowered their price objective on shares of LifeMD from $14.00 to $12.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $12.86.

LifeMD Stock Up 0.8%

NASDAQ:LFMD traded up $0.06 during trading hours on Thursday, hitting $6.88. 1,886,192 shares of the stock traded hands, compared to its average volume of 1,657,852. The firm has a 50 day moving average price of $11.86 and a 200 day moving average price of $8.52. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $15.84. The firm has a market cap of $326.04 million, a price-to-earnings ratio of -32.83 and a beta of 1.72.

Insider Activity at LifeMD

In related news, CEO Justin Schreiber sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.38, for a total transaction of $334,500.00. Following the completion of the transaction, the chief executive officer owned 2,500,721 shares of the company's stock, valued at approximately $33,459,646.98. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Harold Yecies sold 15,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $12.25, for a total transaction of $183,750.00. Following the completion of the sale, the insider owned 16,100 shares of the company's stock, valued at approximately $197,225. The trade was a 48.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 275,000 shares of company stock worth $3,564,550. 18.40% of the stock is currently owned by corporate insiders.

Institutional Trading of LifeMD

A number of institutional investors have recently made changes to their positions in LFMD. Creative Planning bought a new stake in shares of LifeMD during the second quarter valued at approximately $272,000. SG Americas Securities LLC boosted its stake in LifeMD by 97.6% during the second quarter. SG Americas Securities LLC now owns 21,948 shares of the company's stock worth $299,000 after buying an additional 10,843 shares during the period. Calamos Advisors LLC purchased a new position in LifeMD during the second quarter worth $543,000. Geode Capital Management LLC boosted its stake in LifeMD by 7.9% during the second quarter. Geode Capital Management LLC now owns 925,173 shares of the company's stock worth $12,603,000 after buying an additional 67,440 shares during the period. Finally, Pier 88 Investment Partners LLC purchased a new position in LifeMD during the second quarter worth $584,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.